AbbVie agreed to license ex-China rights to two Haisco Pharmaceutical pain compounds in a transaction structured around a $30 million upfront payment for the candidates. The licensing arrangement covers development, manufacturing, and commercialization globally outside mainland China, Hong Kong, and Macau. The agreement adds non-opioid pain assets to AbbVie’s portfolio as large pharma continue to build differentiation in pain therapeutics with less reliance on opioids. The move also signals continued cross-border partnering activity in pain drug development, where companies look to de-risk late-stage timelines by buying access to candidate-specific programs.